Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines

被引:315
作者
Duffy, MJ
van Dalen, A
Haglund, C
Hansson, L
Klapdor, R
Lamerz, R
Nilsson, O
Sturgeon, C
Topolcan, O
机构
[1] St Vincents Univ Hosp, Dept Nucl Med, Dublin 4, Ireland
[2] Univ Coll Dublin, Dept Surg, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland
[3] Inst Tumor Marker Oncol, NL-2801 TG Gouda, Netherlands
[4] Univ Helsinki, Cent Hosp, Dept Surg, Helsinki, Finland
[5] Akad Hosp, Dept Clin Chem & Pharmacol, Uppsala, Sweden
[6] Ctr Clin & Expt Tumour Diag & Therapy, Hamburg, Germany
[7] Univ Munich, Klinikum Grosshadern, Med Klin 2, D-8000 Munich, Germany
[8] CanAg Diagnost, Gothenburg, Sweden
[9] Royal Edinburgh Infirm, Dept Clin Biochem, Edinburgh, Midlothian, Scotland
[10] Univ Hosp, Dept Internal Med 2, Plzen, Czech Republic
关键词
colorectal cancer; CEA; guidelines; tumour markers; EGTM;
D O I
10.1016/S0959-8049(02)00811-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, numerous serum and cell/tissue-based markers have been described for colorectal cancer (CRC). The aim of this article was to provide guidelines for the routine clinical use of some of these markers. Lack of sensitivity and specificity preclude the use of any available serum markers such as carcinoembryonic antigen (CEA), CA 19-9, CA 242, CA 72-4, tissue polypeptide antigen (TPA) or tissue polypeptide-specific antigen (TPS) for the early detection of CRC. However, preoperative measurement of CEA is desirable as this may give independent prognostic information, help with surgical management and provide a baseline level for subsequent determinations. For patients with stage 2 (Dukes' B) and 3 (Dukes' C) disease who may be candidates for liver resection, CEA levels should be measured every 2-3 months for at least 3 years after diagnosis. For monitoring treatment of advanced disease, CEA should also be tested every 2-3 months. Insufficient evidence is presently available to recommend the routine use of other serum markers for monitoring purposes. Similarly, the new cell and tissue-based markers (e.g, ras, P53) cannot yet be recommended for routine clinical use. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:718 / 727
页数:10
相关论文
共 73 条
[1]   Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel [J].
Ahlquist, DA ;
Skoletsky, JE ;
Boynton, KA ;
Harrington, JJ ;
Mahoney, DW ;
Pierceall, WE ;
Thibodeau, SN ;
Shuber, AP .
GASTROENTEROLOGY, 2000, 119 (05) :1219-1227
[2]   Stool screening for colorectal cancer: evolution from occult blood to molecular markers [J].
Ahlquist, DA ;
Shuber, AP .
CLINICA CHIMICA ACTA, 2002, 315 (1-2) :157-168
[3]   Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[4]  
[Anonymous], ANTICANCER RES
[5]   CARCINOEMBRYONIC ANTIGEN (CEA) IN DIAGNOSIS AND PROGNOSIS OF COLORECTAL-CARCINOMA [J].
ARNAUD, JP ;
KOEHL, C ;
ADLOFF, M .
DISEASES OF THE COLON & RECTUM, 1980, 23 (03) :141-144
[6]  
Bast RC, 1996, J CLIN ONCOL, V14, P2843
[7]   Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait [J].
Behbehani, AI ;
Al-Sayer, H ;
Farghaly, M ;
Kanawati, N ;
Mathew, A ;
Al-Bader, A ;
Van Dalen, A .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2000, 15 (01) :51-55
[8]   Surveillance after colorectal cancer resection [J].
Berman, JM ;
Cheung, RJ ;
Weinberg, DS .
LANCET, 2000, 355 (9201) :395-399
[9]   FOLLOW-UP OF PATIENTS WITH COLORECTAL-CANCER - A METAANALYSIS [J].
BRUINVELS, DJ ;
STIGGELBOUT, AM ;
KIEVIT, J ;
VANHOUWELINGEN, HC ;
HABBEMA, JDF ;
VANDEVELDE, CJH .
ANNALS OF SURGERY, 1994, 219 (02) :174-182
[10]   Colon cancer screening [J].
Burt, RW .
GASTROENTEROLOGY, 2000, 119 (03) :837-853